.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,250,542

« Back to Dashboard

Claims for Patent: 5,250,542

Title: Peripherally selective piperidine carboxylate opioid antagonists
Abstract:3,4,4-trisubstitutedpiperidinyl-N-alkylcarboxylates and intermediates for their preparation are provided. These piperidine-N-alkylcarboxylates are useful as peripheral opioid antagonists.
Inventor(s): Cantrell; Buddy E. (Fountaintown, IN), Zimmerman; Dennis M. (Mooresville, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:07/916,783
Patent Claims: 1. A trans-3,4 isomer of a compound of the formula (I) ##STR14## wherein R.sup.1 is hydrogen or C.sub.1 -C.sub.5 alkyl;

R.sup.2 is hydrogen, C.sub.1 -C.sub.5 alkyl or C.sub.2 -C.sub.6 alkenyl;

R.sup.3 is hydrogen, C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, phenyl, cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, cycloalkyl-substituted C.sub.1 -C.sub.3, alkyl C.sub.5 -C.sub.8 cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl or phenyl-substituted C.sub.1 -C.sub.3 alkyl;

wherein:

R.sup.4 is hydrogen, C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl, C.sub.5 -C.sub.8 cycloalkenyl-substituted C.sub.1 -C.sub.3 alkyl or phenyl-substituted C.sub.1 -C.sub.3 alkyl;

R.sup.5 is hydrogen or C.sub.1 -C.sub.3 alkyl;

R.sup.6 is hydrogen, C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, cycloalkyl, phenyl, cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl, C.sub.5 -C.sub.8 cycloalkenyl, C.sub.5 -C.sub.8 cycloalkenyl-substituted C.sub.1 -C.sub.3 alkyl, phenyl-substituted C.sub.1 -C.sub.3 alkyl, or (CH.sub.2).sub.q --B; or

R.sup.5 and R.sup.6 together with N form a saturated non aromatic 4- to 6-membered heterocyclic ring; ##STR15## R.sup.7 is hydrogen or C.sub.1 -C.sub.3 alkyl; R.sup.8 is hydrogen, C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl, cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, C.sub.5 -C.sub.8 cycloalkenyl-substituted C.sub.1 -C.sub.3 alkyl, phenyl or phenyl-substituted C.sub.1 -C.sub.3 alkyl; or

R.sup.7 and R.sup.8 together with N form a saturated non aromatic 4- to 6-membered heterocyclic ring;

W is OR.sup.9, NR.sup.10 R.sup.11, or OE;

R.sup.9 is hydrogen, C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl, C.sub.5 -C.sub.8 cycloalkenyl-substituted C.sub.1 -C.sub.3 alkyl or phenyl-substituted C.sub.1 -C.sub.3 alkyl;

R.sup.10 is hydrogen or C.sub.1 -C.sub.3 alkyl;

R.sup.11 is hydrogen, C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, phenyl, cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl, phenyl-substituted C.sub.1 -C.sub.3 alkyl, ##STR16## R.sup.10 and R.sup.11 together with N form a saturated non aromatic 4- 6-membered heterocyclic ring; ##STR17## R.sup.12 is C.sub.1 -C.sub.3 alkyl substituted methylene, R.sup.13 is C.sub.1 -C.sub.10 alkyl;

D is OR.sup.14 or NR.sup.15 R.sup.16 ;

wherein:

R.sup.14 is hydrogen, C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl, or C.sub.5 -C.sub.8 cycloalkenyl-substituted C.sub.1 -C.sub.3 alkyl or phenyl-substituted C.sub.1 -C.sub.3 alkyl;

R.sup.15 is hydrogen, C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, phenyl, phenyl-substituted C.sub.1 -C.sub.3 alkyl, cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl or C.sub.5 -C.sub.8 cycloalkenyl-substituted C.sub.1 -C.sub.3 alkyl; and

R.sup.16 is hydrogen or C.sub.1 -C.sub.3 alkyl; or

R.sup.15 and R.sup.16 together with N form a saturated non aromatic 4- to 6-membered heterocyclic ring;

Y is OR.sup.17 or NR.sup.18 R.sup.19 ;

R.sup.17 is hydrogen, C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl, C.sub.5 -C.sub.8 cycloalkenyl-substituted C.sub.1 -C.sub.3 alkyl, or phenyl-substituted C.sub.1 -C.sub.3 alkyl;

R.sup.18 is hydrogen or C.sub.1 -C.sub.3 alkyl; and

R.sup.19 is hydrogen, C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, phenyl, cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl, C.sub.5 -C.sub.8 cycloalkenyl-substituted C.sub.1 -C.sub.3 alkyl, or phenyl-substituted C.sub.1 -C.sub.3 alkyl; or

R.sup.18 and R.sup.19 together with N form a saturated non aromatic 4- to 6-membered heterocyclic ring;

n is 0-;

q is 1-4;

m is 1-4;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein R.sup.1 is hydrogen; R.sup.2 is C.sub.1 -C.sub.3 alkyl; n=1 or 2; and R.sup.3 is benzyl, phenyl, cyclohexyl, or cyclohexylmethyl.

3. The compound of claim 2 wherein A is OR.sup.4 and R.sup.4 is hydrogen or C.sub.1 -C.sub.3 alkyl.

4. The compound of claim 2 wherein A is NR.sup.5 R.sup.6 in which R.sup.5 is hydrogen and R.sup.6 is (CH.sub.2).sub.q --B wherein q is 1 to 3 and B is --C(O)W.

5. The compound of claim 4 wherein W is OR.sup.9 and R.sup.9 is hydrogen, C.sub.1 -C.sub.5 alkyl, phenyl-substituted C.sub.1 -C.sub.2 alkyl, C.sub.5 -C.sub.6 cycloalkyl, or C.sub.5 -C.sub.6 cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl.

6. The compound of claim 4 wherein W is NR.sup.10 R.sup.11 in which R.sup.10 is hydrogen or C.sub.1 -C.sub.3 alkyl, and R.sup.11 is hydrogen, C.sub.1 -C.sub.3 alkyl or (CH.sub.2).sub.m C(O)Y.

7. The compound of claim 6 wherein m is 1 to 3 and Y is OR.sup.17 or NR.sup.18 R.sup.19 wherein R.sup.17, R.sup.18 and R.sup.19 are independently hydrogen or C.sub.1 -C.sub.3 alkyl.

8. The compound of claim 4 wherein W is OCH.sub.2 C(O)OD in which D is OR.sup.14 or NR.sup.15 R.sup.16 wherein R.sup.14 is hydrogen or C.sub.1 -C.sub.3 alkyl, R.sup.15 is hydrogen and R.sup.16 is methyl or benzyl.

9. The compound of claim 4 wherein W is OR.sup.12 O C(O)R.sup.13, wherein R.sup.12 is --CH(CH.sub.3)-- or --CH(CH.sub.2 CH.sub.3)-- and R.sup.13 is C.sub.1 -C.sub.3 alkyl.

10. The compound of claim 1 wherein the configuration at positions 3 and 4 of the piperidine ring is each R.

11. The compound of claim 1 selected from the group consisting of

QCH.sub.2 CH[CH.sub.2 (C.sub.6 H.sub.5)]C(O)OH, QCH.sub.2 CH.sub.2 CH(C.sub.6 H.sub.5)C(O)NHCH.sub.2 C(O)-OCH.sub.2 CH.sub.2, QCH.sub.2 CH.sub.2 CH(C.sub.6 H.sub.5)C(O)NHCH.sub.2 C(O)OH, Q-CH.sub.2 CH.sub.2 CH-(C.sub.6 H.sub.5)C(O)NHCH.sub.2 C(O)NHCH.sub.3, Q-CH.sub.2 CH.sub.2 CH(C.sub.6 H.sub.5)C(O)NHCH.sub.2 C(O)-NHCH.sub.2 CH.sub.3, G-NH(CH.sub.2).sub.2 C(O)NH.sub.2, G-NH(CH.sub.2).sub.2 C(O)NHCH.sub.3, G-NHCH.sub.2 C(O)NH.sub.2, G-NHCH.sub.2 C(O)NHCH.sub.3, G-NHCH.sub.3 C(O)NHCH.sub.2 CH.sub.3, G-NH(CH.sub.2).sub.3 C(O)OCH.sub.2 CH.sub.3, G-NH(CH.sub.2).sub.3 C(O)NHCH.sub.3, G-NH(CH.sub.2).sub.2 C(O)-OH, G-NH(CH.sub.2).sub.3 C(O)OH, QCH.sub.2 CH[CH.sub.2 (C.sub.6 H.sub.11)]C(O)NHCH.sub.2 C(O)OH, QCH.sub.2 CH[CH.sub.2 (C.sub.6 H.sub.11)]C(O)NH(CH.sub.2) .sub.2 C(O)OH, QCH.sub.2 CH[CH.sub.2 (C.sub.6 H.sub.11)]-C(O)NH(CH.sub.2).sub.2 C(O)NH.sub.2, Z-NHCH.sub.2 C(O)OCH.sub.2 CH.sub.3, Z-NHCH.sub.2 C(O)OH, Z-NHCH.sub.2 C(O)NH.sub.2, Z-NHCH.sub.2 C(O)N(CH.sub.3).sub.2, Z-NHCH.sub.2 C(O)NHCH(CH.sub.3).sub.2, Z-NHCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, Z-NH(CH.sub.2).sub.2 C(O)OCH.sub.2 (C.sub.6 H.sub.5), Z-NH-(CH.sub.2 C(O)OH, Z-NH(CH.sub.2).sub.2 C(O)NHCH.sub.2 CH.sub.3, Z-NH(CH.sub.2).sub.3 C(O)NHCH.sub.3, Z-NHCH.sub.2 C(O)NHCH.sub.2 C(O)OH, Z-NHCH.sub.2 C(O)OCH.sub.2 C(O)OCH.sub.3, Z-NHCH.sub.2 -C(O)O(CH.sub.2).sub.4 CH.sub.3, Z-NHCH.sub.2 C(O)OCH.sub.2 C(O)NHCH.sub.3, Z-NHCH.sub.2 C(O)O-(4-methoxycyclohexyl), Z-NHCH.sub.2 C(O)OCH.sub.2 C(O)NHCH.sub.2 (C.sub.6 H.sub.5), and Z-NHCH.sub.2 C(O)OCH(CH.sub.3)OC(O)CH.sub.3, wherein: ##STR18## and pharmaceutically acceptable salts thereof.

12. A compound of claim 11 selected from the group consisting of (3R,4R,S)-Z-NHCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (+)Z-NHCH.sub.2 C(O)OH, (--)Z-NHCH.sub.2 C(O)OH, (3R,4R,R)-ZNHCH.sub.2 C(O)-OCH.sub.2 CH(CH.sub.3).sub.2, (3S,4S,S)-ZNHCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (3S,4S,R)-ZNHCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (3R,4R)-ZNHCH.sub.2 C(O)NHCH.sub.2 (C.sub.6 H.sub.5) and (3R,4R)-G-NH(CH.sub.2).sub.3 C(O)OH, and pharmaceutically acceptable salts thereof.

13. A substantially pure stereoisomer of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical formulation comprising a compound of claim 1 or the salt thereof in combination with a pharmaceutically acceptable excipient.

15. A pharmaceutical formulation comprising a compound of claim 11 or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable excipient.

16. A method for treating irritable bowel syndrome in a patient said method comprising administering to said patient an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

17. A method for binding a peripheral opioid receptor in a patient which comprises administering to said patient an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

18. The method of claim 17 wherein said peripheral effect being treated is constipation, nausea or vomiting.

19. A method for blocking mu receptors in mammals comprising administering to a mammal requiring blocking of a mu receptor a receptor blocking dose of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

20. A method for treating idiopathic constipation in a patient said method comprising administering to said patient an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

21. A method of claim 16 wherein the compound is one wherein R.sup.1 is hydrogen; R.sup.2 is C.sub.1 -C.sub.3 alkyl; n=1 or 2; and R.sup.3 is benzyl, phenyl, cyclohexyl, or cyclohexylmethyl.

22. A method of claim 21 wherein the compound is one wherein A is NR.sup.5 R.sup.6 and R.sup.5 is hydrogen, R.sup.6 is (CH.sub.2).sub.q --B, q is 1 to 3 and B is --C(O)W.

23. A method of claim 22 wherein the compound is one wherein W is OR.sup.9 and R.sup.9 is hydrogen, C.sub.1 -C.sub.5 alkyl, phenyl-substituted C.sub.1 -C.sub.2 alkyl, C.sub.5 -C.sub.6 cycloalkyl, or C.sub.5 -C.sub.6 cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl.

24. A method for treating irritable bowel syndrome in a patient comprising administering to the patient an effective amount of a compound of claim 11.

25. A method of claim 24 wherein the compound is selected from the group consisting of (3R,4R,S)-Z-NHCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (+)Z-NHCH.sub.2 C(O)OH, (--)Z-NHCH.sub.2 C(O)OH, (3R,4R,R)-ZNHCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (3S,4S,S)-ZNCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (3S,4S,R)-ZNHCH.sub.2 C(O)OCH.sub.2 CH-(CH.sub.3).sub.2, (3R,4R)-ZNHCH.sub.2 C(O)NHCH.sub.2 (C.sub.6 H.sub.5) and (3R,4R)-G-NH(CH.sub.2).sub.3 C(O)OH.

26. A method of claim 18 wherein the compound is one wherein R.sup.1 is hydrogen; R.sup.2 is C.sub.1 -C.sub.3 alkyl; n=1 or 2; and R.sup.3 is benzyl, phenyl, cyclohexyl, or cyclohexylmethyl.

27. A method of claim 26 wherein the compound is one wherein A is NR.sup.5 R.sup.6 and R.sup.5 is hydrogen, R.sup.6 is (C.sub.2).sub.q --B, q is 1 to 3 and B is --C(O)W.

28. A method of claim 27 wherein the compound is one wherein W is OR.sup.9 and R.sup.9 is hydrogen, C.sub.1 -C.sub.5 alkyl, phenyl-substituted C.sub.1 -C.sub.2 alkyl, C.sub.5 -C.sub.6 cycloalkyl, or C.sub.5 -C.sub.6 cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl.

29. A method for binding a peripheral opioid receptor in a patient which comprises administering to said patient an effective amount of a compound of claim 11.

30. A method of claim 29 wherein the compound is one selected from the group consisting of (3R,4R,S)-Z-NHCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (+)Z-NHCH.sub.2 C(O)OH, (--)Z-NHCH.sub.2 C(O)OH, (3R,4R,R)-ZNHCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (3S,4S,S)-ZNCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (3S,4S,R)-ZNHCH.sub.2 C(O)OCH.sub.2 CH-(CH.sub.3).sub.2, (3R,4R)-ZNHCH.sub.2 C(O)NHCH.sub.2 (C.sub.6 H.sub.5) and (3R,4R)-G-NH(CH.sub.2).sub.3 C(O)OH.

31. A method of claim 19 wherein the compound is one wherein R.sup.1 is hydrogen; R.sup.2 is C.sub.1 -C.sub.3 alkyl; n=1 or 2; and R.sup.3 is benzyl, phenyl, cyclohexyl or cyclohexylmethyl.

32. A method of claim 31 wherein the compound is one wherein A is NR.sup.5 R.sup.6 and R.sup.5 is hydrogen, R.sup.6 is (CH.sub.2).sub.q --B, q is 1 to 3 and B is --C(O)W.

33. A method of claim 32 wherein the compound is one wherein W is OR.sup.9 and R.sup.9 is hydrogen, C.sub.1 -C.sub.5 alkyl, phenyl-substituted C.sub.1 -C.sub.2 alkyl, C.sub.5 -C.sub.6 cycloalkyl, or C.sub.5 -C.sub.6 cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl.

34. A method for blocking a mu receptor in a mammal comprising administering to a mammal requiring blocking of a mu receptor a receptor blocking dose of a compound of claim 11.

35. A method of claim 34 wherein the compound is one selected from the group consisting of (3R,4R,S)-Z-NHCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (+)Z-NHCH.sub.2 C(O)OH, (--)Z-NHCH.sub.2 C(O)OH, (3R,4R,R)-ZNHCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (3S,4S,S)-ZNCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (3S,4S,R)-ZNHCH.sub.2 C(O)OCH.sub.2 -CH(CH.sub.3).sub.2, (3R,4R)-ZNHCH.sub.2 C(O)NHCH.sub.2 (C.sub.6 H.sub.5) and (3R,4R)-G-NH(CH.sub.2).sub.3 C(O)OH.

36. A method of claim 20 wherein the compound is one wherein R.sup.1 is hydrogen; R.sup.2 is C.sub.1 -C.sub.3 alkyl; n=1 or 2; and R.sup.3 is benzyl, phenyl, cyclohexyl, or cyclohexylmethyl.

37. A method of claim 36 wherein the compound is one wherein A is NR.sup.5 R.sup.6 and R.sup.5 is hydrogen, R.sup.6 is (CH.sub.2).sub.q --B, q is 1 to 3 and B is --C(O)W.

38. A method of claim 37 wherein the compound is one wherein W is OR.sup.9 and R.sup.9 is hydrogen, C.sub.1 -C.sub.5 alkyl, phenyl-substituted C.sub.1 -C.sub.2 alkyl, C.sub.5 -C.sub.6 cycloalkyl, or C.sub.5 -C.sub.6 cycloalkyl-substituted C.sub.1 -C.sub.3 alkyl.

39. A method for treating idiopathic constipation in a patient comprising administering to the patient an effective amount of a compound of claim 11.

40. A method of claim 39 wherein the compound is one selected from the group consisting of (3R,4R,S)-Z-NHCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (+)Z-NHCH.sub.2 C(O)OH, (--)Z-NHCH.sub.2 C(O)OH, (3R,4R,R)-ZNHCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (3S,4S,S)-ZNHCH.sub.2 C(O)OCH.sub.2 CH(CH.sub.3).sub.2, (3S,4S,R)-ZNHCH.sub.2 C(O)OCH.sub.2 CH-(CH.sub.3).sub.2, (3R,4R)-ZNHCH.sub.2 C(O)NHCH.sub.2 (C.sub.6 H.sub.5) and (3R,4R)-G-NH(CH.sub.2).sub.3 C(O)OH.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc